US-based life sciences firm AOBiome has started enrolling patients in a Phase Ib/IIa clinical trial of its ammonia oxidising bacteria (AOB) product candidate to treat seasonal allergic rhinitis (SAR).

AOB platform is a patented, proprietary, topical and intranasal formulation incorporating a single strain of beneficial AOB, Nitrosomonas eutropha. It is designed to repopulate the skin or nasal microbiome with AOB normally found on the body.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Once administered, AOB converts ammonia to nitrite, which is known to have antibacterial properties, and to nitric oxide, a signalling molecule found to regulate inflammation and vasodilation.

AOBiome president Todd Krueger said: “AOBiome continues its leadership in innovation with the initiation of what we believe is the first FDA-supported clinical study to test intranasal application of a microbiome-targeted therapy.

“The SAR trial is designed to provide early evidence for the potential efficacy of our approach as a prophylactic treatment for those who suffer from seasonal allergies.

“In addition, we look forward to establishing safety and tolerability with another route of delivery, which will allow us to pursue a broader range of diseases that are amenable to intranasal delivery.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
“The SAR trial is designed to provide early evidence for the potential efficacy of our approach as a prophylactic treatment for those who suffer from seasonal allergies.”

The company noted that its AOB formulations have so far been tested in more than 270 people, with no serious consequences and no difference in adverse events between treatment and vehicle groups.

The randomised, double-blind, vehicle-controlled Phase Ib/IIa trial is designed to evaluate safety and tolerability of the company’s AOB product candidate in up to 24 healthy volunteers and preliminary efficacy as a prophylaxis therapy in 42 people with a history of SAR caused by ragweed pollen.

AOBiome chief medical officer Larry Weiss said: “Current treatments for SAR are frequently associated with local and/or systemic adverse effects that can cause many patients to pursue alternative strategies for control of their symptoms.

“Our platform seeks to address SAR through a novel approach, adjusting human commensal bacteria in the nasal microbiome to rebalance inflammatory processes underlying disease. We look forward to sharing the progress of our clinical program utilising intranasal delivery.”

Image: Illustration depicting inflammation associated with allergic rhinitis. Photo: courtesy of BruceBlaus.